GPT-Rosalind, Explained: What OpenAI's First Life Sciences Model Actually Changes for Pharma R&D
GPT-Rosalind explained OpenAI's first life sciences model, its benchmarks, gated access, and implications for global pharma R&D teams.
Ravindra Warang | May 06, 2026
How Anti-CD8 Alpha Antibody Helps in Determining Failure of a Treatment
Discover how anti-CD8 Alpha antibody helps researchers track T-cell response in immunotherapy and cancer diagnostics.
Team Pharma Now | Apr 14, 2026
Computer System Validator (CSV) vs. Computer System Assurance (CSA): What Are the Main Differences?
Guide to Computer System Validation (CSV) vs Computer Software Assurance (CSA) in pharma with key differences and risk-based approach.
Vaibhavi M. | Apr 10, 2026
PROTACs and Molecular Glues: How Targeted Protein Degradation Is Redefining Drug Discovery
How PROTACs and molecular glues are redefining drug discovery through targeted protein degradation strategies.
Mrudula Kulkarni | Feb 13, 2026
20260213135839.webp&w=1440&q=75 "Neuroinflammation As A Target Class: The New Frontier In CNS Drug Development")
Neuroinflammation As A Target Class: The New Frontier In CNS Drug Development
Why neuroinflammation is emerging as a major target class reshaping CNS drug development and neurology research.
Vaibhavi M. | Feb 13, 2026
Subscribe to our Newsletter!
Be the first to get exclusive offers and the latest news